Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal Hydrocortisone for Postoperative Pain and CRP After Caesarean Section
NCT07892547Phase 4
Key facts
- Status
- Completed
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Countries
- 1
- Drugs
- hydrocortisone
- Conditions
- postoperative painperitonitis
01
Overview
Phase 4, randomised, double-blind trial in postoperative pain and peritonitis comparing Hydrocortisone Group with Placebo Group (2 arms). Primary endpoint: Postoperative Pain Intensity at 24 hours. Started Jun 2026; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Hydrocortisone Group
Received 100 mg hydrocortisone dissolved in 100 mL NaCl 0.9% administered intraperitoneally.
Placebo Group
Received 100 mL NaCl 0.9% administered intraperitoneally as a placebo comparator.
03
Who it enrols
Term pregnant women aged 18-40 scheduled for elective Caesarean section under spinal anaesthesia, ASA I-II, without hypersensitivity to corticosteroids, recent corticosteroid use, diabetes requiring medication, coagulation disorders, or active infection.
04
Endpoints
Primary
Postoperative Pain Intensity
Secondary
Serum C-Reactive Protein Levels
Total 24-hour rescue analgesic consumption
Incidence of corticosteroid-related adverse effects
Beyond the preview
Go deeper on NCT07892547.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07892547.